Tscan Therapeutics is trading 5.6% down now at $0.32, with no new company-specific announcement identified for September 18, 2026.
- The latest major update remains the September 2 strategic reorganization, including a workforce reduction and paused ALLOHA-2 enrollment.
- September 8 analyst downgrades are stale context, while broader biotech strength does not explain the decline; the immediate catalyst remains unclear.